Survival benefits for non-small cell lung cancer patients treated with adaptive radiotherapy. (March 2022)

• Record Type: Journal Article
• Authors: Møller, Ditte Sloth; Lutz, Christina Maria; Khalil, Azza Ahmed; Alber, Markus; Holt, Marianne Ingerslev; Kandi, Maria; Schmidt, Hjørdis Hjalting; Tvilum, Marie; Appelt, Ane; Knap, Marianne Marquard; Hoffmann, Lone
• Is Part Of: Radiotherapy and oncology. Volume 168(2022)
• Page Start: 234
• Page End: 240
• Publication Date: 2022-03
• Subjects: NSCLC -- Adaptive radiotherapy -- Pneumonitis -- Survival -- Image guided radiotherapy; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2022.01.039
• Languages: English
• ISSNs: 0167-8140

Abstract

Highlights: Tumor match and adaptive radiotherapy allows for decreased margins while maintaining loco-regional control. Tumor match and adaptive radiotherapy significantly reduces the risk of pneumonitis. After tumor match and adaptive radiotherapy, we observed a significantly improved progression-free and overall survival. Abstract: Introduction: Tumor match and adaptive radiotherapy based on on-treatment imaging increases the precision of RT. This allows a reduction of treatment volume and, consequently, of the dose to organs at risk. We investigate the clinical benefits of tumor match and adaptive radiotherapy for a cohort of non-small cell lung cancer patients (NSCLC). Methods: In 2013, tumor match and adaptive radiotherapy based on daily cone-beam CT scans was introduced to ensure adaption of the radiotherapy treatment plan for all patients with significant anatomical changes during radiotherapy. Before 2013, the daily cone-beam CT scans were matched on the vertebra and anatomical changes were not evaluated systematically. To estimate the effect of tumor match and adaptive radiotherapy, 439 consecutive NSCLC patients treated with definitive chemo-radiotherapy (50–66 Gy/25–33 fractions, 2010–2018) were investigated retrospectively. They were split in two groups, pre-ART (before tumor match and adaptive radiotherapy, 184 patients), and ART (after tumor match and adaptive radiotherapy, 255 patients) and compared with respect to clinical, treatment-specific and dosimetric variables ( χ 2 tests, Mann Whitney U tests), progression, survival and radiation pneumonits (CTCAEv3). Progression-free and overall survival as well as radiation pneumonitis were compared with log-rank tests. Hazard ratios were estimated from Cox proportional hazard regression. Results: No significant differences in stage ( p = 0.36), histology ( p = 0.35), PS ( p = 0.12) and GTV volumes ( p = 0.24) were observed. Concomitant chemotherapy was administered more frequently in the ART group (78%) compared to preART (64%), p < 0.001. Median[range] PTV volumes decreased from 456 [71;1262] cm 3 (preART) to 270 [31;1166] cm 3 (ART), p < 0.001, thereby significantly reducing mean doses to lungs (median, preART 16.4 [1.9;24.7] Gy, ART 12.1 [1.7;19.4] Gy, p < 0.001) and heart (median, preART 8.0 [0.1;32.1] Gy, ART 4.4 [0.1;33.9] Gy, p < 0.001). The incidence of RP at nine months decreased significantly with ART (50% to 20% for symptomatic RP (≥G2), 21% to 7% for severe RP (≥G3), 6% to 0.4% for lethal RP (G5), all p < 0.001). The two-year progression free survival increased from 22% (preART) to 30% (ART), while the overall survival increased from 43% (preART) to 56% (ART). The median overall survival time increased from 20 (preART) to 28 months (ART). Conclusion: Tumor match and adaptive radiotherapy significantly decreased radiation pneumonitis, while maintaining loco-regional control. Further, we observed a significantly improved progression-free and overall survival.